Abstract: Cutaneous melanoma is the solid neoplasia with the highest growing incidence among all tumors. It spreads predictably to the lymphatic vessels and sentinel lymph node, and when the latter is affected the prognosis worsens dramatically. Sentinel lymph node biopsy is considered when thickness of the primary tumor exceeds 1mm and/or when there are adverse features in thinner melanomas. When there is nodal metastasis, current evidence in the literature recommends complete lymphadenectomy, although this procedure has its intrinsic risks (i.e., lymphedema and cellulitis), and there are no published clinical trials proving additional overall survival benefits. The current in-depth literature review thus aims to identify patients that will benefit most from the procedure, including those with the highest likelihood of presenting additional affected lymph nodes in the same nodal basin. The authors also discuss techniques for identification of the sentinel lymph node, false-negative rates, and predictive models for lymph node involvement. In conclusion, complete elective lymphadenectomy should always be discussed on a case-by-case basis when metastases are detected in the sentinel lymph node.
INTRODUCTION
Cutaneous melanoma (CM) is associated with high lethality. It is currently the malignant neoplasm with the fastest growing incidence of all the tumors, having increased 15-fold in the last 40 years in the United States alone. 1 Most CMs spread first to the lymphatics, with the sentinel lymph node (SLN) as the first lymph node to receive lymphatic drainage from the skin where the primary lesion is located. 6-Clark level IV or greater. 2 Currently, regression of the primary lesion is no longer considered a predictor of SLN involvement and is thus not used to indicate SLN biopsy. 3, 4 When conventional histopathology fails to identify SLN micrometastases, immunohistochemistry (IHC) is indicated, with the S100, HMB-45, and MART-1/Melan-A proteins as the target antigens. Molecular biology techniques such as RT-PCR (reverse transcription-polymerase chain reaction) and cell culture can identify even smaller amounts of metastatic cells in the sentinel lymph node, but they still lack clinical applicability in this scenario. SLN is the most important prognostic factor for patients with localized CM. [5] [6] [7] [8] SLN biopsy replaced elective lymphadenectomy in patients with clinically localized melanoma at high risk of lymph node metastasis. The current gold standard for patients with negative sentinel lymph node is clinical observation and monitoring of the nodal basin, and ultrasound can be considered in the follow-up.
SENTINEL LYMPH NODE BIOPSY

MANAGEMENT OF THE PATIENT WITH POSITIVE SENTINEL LYMPH NODE
Traditionally, complete lymphadenectomy (CL) has been indicated in patients with positive SLN. 2 When lymphadenectomy is performed, the treatment goal is to remove other lymph nodes with metastases and theoretically interrupt spread of the melanoma to other organs. Metastases to non-sentinel lymph nodes have been observed in some 15 -20% of specimens obtained from CL.
9,10
The therapeutic effect of CL for patients without non-sentinel lymph node metastasis is unknown.
In addition to the possible therapeutic effect of complete lymphadenectomy, the approach stratifies nodal involvement as N1 (one lymph node involved), N2 (two to three lymph nodes involved), and N3 (four or more lymph nodes involved). The eighth edition of the AJCC Staging System adopts the nomenclature "a" (if detected by SLN biopsy), "b" (if detected clinically), or "c" (when in-transit or satellite lesions or microsatellite metastases are detected). 11 Ten-year melanoma-specific survival differs considerably according to the nodal staging: 75% of N1 patients, 68% for N2, and only 47% for N3. 12 The identification of risk factors for non-sentinel lymph node involvement among the patient's clinical characteristics and those of the primary lesion and sentinel lymph node can be used to select CM patients with SLN lymph node involvement that will not benefit from lymphadenectomy, thus preventing sequelae from the procedure.
Oncologists are currently debating whether or not to per- in the SLN (66% of cases), and no difference was found in metastasis-free survival between the group with "dissected" nodal chain versus the group with spared nodal chain and followed with trimonthly ultrasound. The authors concluded that CL should not be performed in cases in which the SLN presents micrometastasis ≤ 1.0mm. 15 It should be noted that the authors reported difficulty in enrolling patients into a supposedly suboptimal therapy, and there was a clear decrease in statistical power from 80% to 50%, which could not be resolved by increasing the follow-up.
PRINCIPAL STUDIES AND RESULTS
In the wake of DeCOG-SLT, in the MSLT-II study, 1,934 patients with positive sentinel lymph node detected by histopathology or RT-PCR were randomized to receive immediate complete lymphadenectomy or watchful waiting with ultrasound. The primary outcome was melanoma-specific survival and the secondary outcomes were disease-free survival and non-sentinel lymph node involvement. The trial was negative for the primary outcome, essentially
showing the same 86% three-year MSS in both study arms, even in the subgroup analysis. However, disease-free survival favored the lymphadenectomy arm by 5%, due mainly to a 69% difference in regional lymph node disease-free survival, but with no change in distant disease-free survival. The authors concluded that complete lymphadenectomy following positive SLN biopsy can be waived, especially to spare patients from lymphedema (24% in CL versus 6% in watchful waiting), since it had no impact on melanoma-specific survival, especially in patients with little nodal deposit in the SLN and who were willing to undergo rigorous ultrasound follow-up.
Importantly, however, the study showed lower regional disease control and less precise prognostic stratification. Gershenwald et al. reassessed the histopathological examination of false-negative SLNs with serial slices of the lymph node and found occult metastases in five of seven patients who had nodal disease as the first site of recurrence. 26 Finally, failure may be due to the presence of occult in-transit metastases that have still not reached the lymph node.
The addition of single photon emission computed tomography (SPECT-CT )to planar lymphoscintigraphy facilitates SLN identification and localization in CM, thereby decreasing the false-negative rate. 27 Fluorescence, using hybrid tracers like indocyanine green and technetium-labelled nanocolloid (99mTc), is a promising method for improving surgical precision in SLN biopsy. It promises to be highly useful for excising sentinel lymph nodes in difficult locations such as head and neck, mediastinum, and retroperitoneum. 28 The addition of activated charcoal to vital dye increases the precision in the identification of the true SLN. suggested by a study that found this incidence in SLN biopsies in patients without a history of melanoma. 30 The most plausible explanations are the existence of nodal nevi and melanocytes that gained access to the lymphatics due to prior skin biopsy. 31 To mitigate the Center bases its approach on the size/ulceration score. 41 The Rotterdam system is currently the most widely used. 42 Based on these scores, when the patient is spared of CL, lymph node basin ultrasound plays an important role in follow-up.
The test allows diagnosing early recurrence, and fine needle aspiration biopsy (FNAB) is performed in the suspicious lymph nodes.
However, the technique is operator-dependent, which requires the patient's availability for trimonthly ultrasound in the first year of follow-up, in addition to displaying some loss of sensitivity for lesions measuring less than 10mm. 
